In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 32.8%. VYGR’s earnings beat ...

The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRAS G12C inhibitor Lumakras as part of a combination regimen for adults with metastatic colorectal cancer (mCRC ...

Amgen's pathfinder KRAS inhibitor Lumakras has been shown to be effective in KRAS-mutated non-small cell lung cancer (NSCLC) in a phase 3 trial that should serve as a confirmation study for its ...

Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in ...

(RTTNews) - Amgen Inc. (AMGN), Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination therapy for the treatment of patients with KRAS G12C ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...

KRAS G12C inhibitors like sotorasib (Lumakras) and adagrasib (Krazati) have been effective for some patients whose cancers harbor this mutation, but many patients’ cancers are resistant to ...

Notably, findings from the phase 3 CodeBreaK 300 trial have supported the use of a combination of Lumakras (sotorasib) and Vectibix (panitumumab) for patients with KRAS G12C-mutated metastatic ...